17.31
Adma Biologics Inc stock is traded at $17.31, with a volume of 1.82M.
It is up +0.64% in the last 24 hours and down -3.03% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$17.20
Open:
$17.23
24h Volume:
1.82M
Relative Volume:
0.56
Market Cap:
$4.13B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
21.11
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
-1.59%
1M Performance:
-3.03%
6M Performance:
+7.65%
1Y Performance:
+27.47%
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ADMA
Adma Biologics Inc
|
17.31 | 4.07B | 426.45M | 197.67M | 110.10M | 0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-23 | Resumed | Raymond James | Strong Buy |
Oct-13-22 | Initiated | Mizuho | Buy |
Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-04-19 | Initiated | Jefferies | Buy |
Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
Feb-07-19 | Resumed | H.C. Wainwright | Buy |
Dec-11-17 | Reiterated | Maxim Group | Buy |
Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
Jul-25-16 | Reiterated | Maxim Group | Buy |
May-13-15 | Reiterated | Maxim Group | Buy |
Dec-08-14 | Initiated | Oppenheimer | Outperform |
Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
What analysts say about ADMA Biologics Inc. stockTremendous portfolio expansion - jammulinksnews.com
Is ADMA Biologics Inc. a good long term investmentFree Consultation - Autocar Professional
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength - MSN
What drives ADMA Biologics Inc. stock priceExceptional growth trajectory - Autocar Professional
ADMA Biologics Inc. Stock Analysis and ForecastMassive portfolio appreciation - jammulinksnews.com
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
We Think ADMA Biologics (NASDAQ:ADMA) Can Manage Its Debt With Ease - 富途牛牛
Institutional investors in ADMA Biologics, Inc. (NASDAQ:ADMA) lost 9.6% last week but have reaped the benefits of longer-term growth - simplywall.st
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
ADMA Biologics Plunges 4.89% Amid Insider Selling Concerns - AInvest
ADMA Biologics Shares Plunge 5.84% Amid Insider Trading Concerns - AInvest
How ADMA Biologics Inc. stock performs during market volatility3x Return Stock Radar - beatles.ru
ADMA Biologics' Insider Transactions: A Strategic Exit or a Vote of Confidence? - AInvest
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors - Yahoo Finance
ADMA Biologics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
ADMA Biologics, Inc. Rings the Opening Bell - Nasdaq
Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
(ADMA) Proactive Strategies - news.stocktradersdaily.com
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - Yahoo Finance
(ADMA) Investment Analysis - news.stocktradersdaily.com
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Implied Volatility Surging for ADMA Biologics Stock Options - TradingView
Will Strong Asceniv Sales Drive ADMA Biologics Further? - Zacks Investment Research
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? - Yahoo Finance
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios - Insider Monkey
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market - Nasdaq
ADMA Biologics (ADMA) Drops for 5th Consecutive Day – Here’s Why - Insider Monkey
(ADMA) On The My Stocks Page - news.stocktradersdaily.com
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):